Clarivate Epidemiology’s coverage of alopecia areata (AA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which…
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic neuroinflammatory disorder that can lead to blindness and paralysis. Most patients have a relapsing form of the disease, leading to…
The type 2 diabetes (T2D) therapy market will expand over the first half of the 2020-2030 forecast period. This increase will partly be fueled by a rich pipeline of novel agents, including emerging…
With an increasing prevalence due to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers and drug launches will…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The current standard of care fails to halt the frequent progression of DN to kidney…
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed in…
Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the arteries in the lower extremities. This condition is considered a major marker for systemic…
Clarivate Epidemiology's coverage of allergic rhinitis (AR) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…
A series of launches are expected to continue to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market in the next 10 years and challenge the dominance of the TNF inhibitors,…
Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…
Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…
Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…
DRG Epidemiology’s coverage of narcolepsy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key hepatitis B virus (HBV) patient populations covering 171 countries…